Home-grown medtech Vaxxas, which wants to disrupt the 170-year-old method of delivering vaccines by needles with a painless patch, has launched a monster $100 million private round to bankroll clinical trials of its top-three products.

Street Talk can reveal Vaxxas has mandated Wilsons Advisory and JPMorgan to steer the raise, with the Wall Street bank on hand to field offshore investor interest. A flyer is in front of potential investors, who are being offered meetings with CEO David Hoey and chief financial officer CFO Doug Cubbin next week as well as access to the data room upon signing non-disclosure agreements.